Cerenome Announces Up to $20 Million Financing Facility with Royalty-Based Repayment
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/30/2026
- S&P 500 flat as higher bond yields counter tech optimism
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
- Risk appetite remains concentrated in large-cap stocks, Citi says
- Netflix stock: Deutsche Bank gets bullish as valuation leaves room to run
- CarMax shares rise over 2% on strong earnings and revenue beat
- Salesforce agrees to acquire AI research platform Listen Labs
- Workday cuts 2.5% of workforce, revises GAAP margin outlook
- S&P 500 flat as higher bond yields counter tech optimism
- Wells Fargo raises oil price targets citing ongoing supply risks
- Anthropic prospectus shows $2T IPO ambition, warns of AI 'existential risk'
Cerenome secures $20M financing deal with royalty-based repayments
September 10, 2026 7:15 AM EDTCerenome, Inc. (NASDAQ: CNSY), a central nervous system oncology company, announced it has entered into a senior secured financing agreement with 3i, LP for up to $20 million with royalty-based repayments.
Under the agreement, the company received initial funding at closing, with additional tranches available... More
